Johnson & Johnson

JNJ · NYSE · USD

Can newer medicines such as TREMFYA, ICOTYDE and INLEXZO grow fast enough to deliver double-digit growth while MedTech slows and litigation costs persist?

Last 4 earnings calls · through Q3 FY2026

Bull case

  • New drug launch contribution

    The bull case rests on newer medicines like TREMFYA, ICOTYDE and INLEXZO carrying growth as older products fade, with each launch adding patients faster than expected.

  • Segment mix shifts to drugs

    Because Innovative Medicine is now the larger and faster-growing segment, gains there can outweigh a slower medical device business for the group as a whole.

  • Pipeline breadth

    A portfolio of many billion-dollar products and a deep pipeline means no single patent loss or trial failure can derail the company's growth plan.

  • Cash generation and returns

    Strong cash generation lets the company fund research, absorb acquisition charges and keep raising the dividend through a period of heavier spending.

Bear case

  • MedTech growth slowdown

    The bear case points to a medical device business that has repeatedly missed its own bar, with heart recovery volumes and overseas demand both weaker than planned.

  • Margin guidance reversal

    Profitability has weakened as acquisition charges, tariffs and launch spending arrive together, and management now guides margins down rather than up for the year.

  • Litigation overhang

    The talc settlement depends on nearly all claimants agreeing, so a large unresolved liability stays on the balance sheet if participation falls short.

  • Patent and pricing pressure

    Government price setting and biosimilar competition erode the older medicine base, so the newer drugs must grow fast enough to replace lost revenue.

Bull and bear points

Growth & Execution

In short: New drug launches are driving Innovative Medicine, while MedTech growth has fallen short of targets.

Bull · 1

  • Orthopaedics separation moves from review to a spin

    Earlier management said it was weighing all separation routes; it now names a spin as the preferred option, which firms the mid-2027 timetable for removing a slower-growth unit.

    Tone shiftQ1 FY2026 → Q3 FY2026
Bear · 2

  • MedTech growth fell to 2.5% in the third quarter

    The device segment grew far slower than the pharmaceutical business, and management told analysts the result was below both its internal standard and the expectations it had given investors.

    Q3 FY2026 call

  • Heart recovery recovery pushed out to 2027

    Earlier management described Impella as facing no meaningful competitor and growing double digits; it now expects corrective action and a return to growth only as trial data arrive in 2027.

    Tone shiftQ1 FY2026 → Q3 FY2026

Profitability & Financial Strength

In short: Free cash flow covers the dividend, while acquisition charges and tariffs are squeezing margins this year.

Bull · 1

  • Base earnings growth near 9% before deal charges

    Stripping out the one-time Firefly Bio and Cell BioMedicines charges, management said reported earnings per share growth would approach 9%, which it presents as the run-rate of the underlying business.

    Q3 FY2026 call
Bear · 2

  • Margin guidance flipped from expansion to a decline

    At the start of the year management guided to at least 50 basis points of operating margin improvement; it now expects roughly a 60 basis point decline after two oncology deals added research charges.

    Tone shiftQ1 FY2026 → Q3 FY2026

  • Acquisition research charges drag reported operating margin

    A roughly $1 billion in-process research charge for Firefly Bio plus Cell BioMedicines deal costs pulled the operating margin down 4.5 points from a year earlier, so reported profit understates the base business.

    Q3 FY2026 call

Market Position

In short: It leads in myeloma and immunology, while patent expirations and talc litigation weigh on results.

Bull · 2

  • Myeloma portfolio reaches patients at every line of therapy

    Management says 80% of multiple myeloma patients receive one of its medicines during treatment, which gives the company several ways to hold revenue as individual drugs meet competition.

    Q3 FY2026 call

  • Mapping system ties ablation procedures to its catheters

    The company cites a study in which patients treated with pulsed-field ablation devices guided by its CARTO mapping system were 61% less likely to be readmitted, evidence it uses to defend share and pricing.

    Q4 FY2025 call
Bear · 2

  • Talc settlement requires 95% claimant participation

    The $5.5 billion ovarian talc agreement takes effect only if nearly all claimants join, so the liability and the legal spending around it stay open if that threshold is missed.

    Q3 FY2026 call

  • Medicare price setting reaches more of the drug portfolio

    Under the Inflation Reduction Act certain products face government-set Medicare prices starting in 2026, which adds to biosimilar competition in capping what the older medicines can earn.

    10-K, filed 2026-02-11